Sánchez Palacios A, Sánchez Palacios M A, García Marrero J A
Allergology Service, Hospital Insular de Las Palmas de Gran Canaria.
Allergol Immunopathol (Madr). 1992 Jul-Aug;20(4):135-8.
Topical nasal immunotherapy (TNI) is a therapeutic option in residual rhinitis. Adverse reactions are common with pollen extracts and often are related to the phenol and thimerosal conservatives. This study sought to determine the clinical effectiveness of two methods of administration of TNI. Twenty-eight patients with allergic perennial rhinitis treated for 2 years with parenteral semidepot immunotherapy were divided into two groups of 14 patients: group A receiving conventional aerosol nebulization (TNE), and group B, which received TNAI using a type F aerosol electrocompressor. Clinical response and tolerance to TNI were evaluated using scores for signs and symptoms. The conclusions were: Both group A and group B exhibited statistically significant differences between baseline and post-immunotherapy parameters (p < 0.001). There were no statistically significant differences in the degree of improvement achieved in the two groups. The main advantages of TNAI were better tolerance of the D. pteronyssinus extracts, perhaps due to the elimination of conservatives, and the guarantee of correct administration of the dose and control of minimum reactions. For these reasons it is a viable therapeutic option in allergic perennial rhinitis previously treated for two years with parenteral semidepot immunotherapy.
局部鼻内免疫疗法（TNI）是治疗残留性鼻炎的一种选择。花粉提取物常引发不良反应，且这些反应通常与苯酚和硫柳汞防腐剂有关。本研究旨在确定两种TNI给药方法的临床效果。28例接受了两年肠胃外半长效免疫疗法治疗的常年性变应性鼻炎患者被分为两组，每组14例：A组接受传统雾化吸入（TNE），B组使用F型雾化电动压缩机接受TNAI。使用体征和症状评分评估对TNI的临床反应和耐受性。结论如下：A组和B组在免疫治疗前和免疫治疗后的参数之间均呈现出具有统计学意义的差异（p < 0.001）。两组所取得的改善程度无统计学意义上的差异。TNAI的主要优势在于对屋尘螨提取物具有更好的耐受性，这可能是由于去除了防腐剂，并且能保证剂量的正确给药以及对最小反应的控制。基于这些原因，对于先前接受了两年肠胃外半长效免疫疗法治疗的常年性变应性鼻炎患者而言，它是一种可行的治疗选择。
